Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fasting Condition

This study has been completed.
Sponsor:
Information provided by:
Dr. Reddy's Laboratories Limited
ClinicalTrials.gov Identifier:
NCT01052129
First received: January 8, 2010
Last updated: May 26, 2010
Last verified: May 2010

January 8, 2010
May 26, 2010
May 2006
May 2006   (final data collection date for primary outcome measure)
Bioequivalence based on Cmax and AUC parameters [ Time Frame: 2 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01052129 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fasting Condition
Open Label Randomised,Two-treatment,Two-period,Two-sequence,Single-dose, Crossover,Comparative Bioequivalence Study of Naproxen Sodium 550 mg Tablets With ANAPROX® DS 550 mg Tablets in Healthy,Adult, Human Subjects Under Fasting Conditions

An open label randomised, two-treatment, two-period, two-sequence, single-dose, crossover, comparative bioequivalence study.

The study was an open label, randomised, two-treatment,two-period, two-sequence, single-dose, crossover,comparative bioequivalence study of Naproxen Sodium 550 mg tablets (containing naproxen 500 mg) manufactured by Dr. Reddy's Laboratories, ltd, Generics, India compared with ANAPROX® OS 550 mg tablets (containing naproxen 500 mg) of Roche Pharmaceuticals, Roche Laboratories Inc. 340 Kingsland Street, Newjersy; in healthy,adult, human subjects under fasting conditions with a wash out period of 10 days between two periods.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Healthy
Drug: Naproxen sodium
Naproxen Sodium Tablets 550 mg
Other Name: Anaprox
  • Experimental: Naproxen Sodium 550 mg Tablets
    Naproxen Sodium 550 mg Tablets of Dr.Reddy's Laboratories Limited
    Intervention: Drug: Naproxen sodium
  • Active Comparator: Anaprox DS 550 mg Tablets
    Anaprox DS 550 mg Tablets of Roche Pharmaceuticals Inc
    Intervention: Drug: Naproxen sodium
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
26
May 2006
May 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy human subjects within the age range of 18 to 45 years.
  • Non-smokers since at least six months.
  • Willingness to provide written informed consent to participate in the study.
  • Body-mass index of ≥18.5 kg/m2 and≤ 24.9 kglm2, with body weight not less than 50 kg.
  • Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluations, medical history or physical examination during the screening.
  • Normal 12-lead ECG or one with abnormality considered to be clinically insignificant.
  • Normal chest X-ray PA view.
  • Comprehension of the nature and purpose of the study and compliance with the requirement of the protocol.
  • Female Subjects:

    • of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence, or
    • postmenopausal for at least 1 year, or
    • surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject.

Exclusion Criteria:

  • Personal/family history of allergy or hypersensitivity to Omeprazole or allied drugs.
  • Past history of anaphylaxis or angioedema.
  • Any major illness in the past three months or any clinically significant ongoing chronic medical illness .e.g. congestive heart failure, hepatitis, pancreatitis etc.
  • Presence of any clinically significant abnormal values during screening e.g. significant abnormality of Liver Function Test (LFT), Renal (kidney) Function Test (RFT), etc.
  • Any cardiac, renal or liver impairment, any other organ or system impairment.
  • History of seizure or psychiatric disorders.
  • Presence of disease markers of HIV 1 and 2, and hepatitis B and C virus
  • Consumption of alcohol for more than two years, or consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and during the study [one drink is equal to one unit of alcohol [one glass wine, half pint beer, and one measure (one ounce) of spirit].
  • Consumption of xanthine containing derivatives (coffee, tea, cola drinks, chocolate) within 48 hours before check-in of each period.
  • Use of any recreational drug or a history of drug addiction.
  • Participation in any clinical trial within the past 3 months.
  • Inaccessibility of veins in left and right arm.
  • Donation of blood (one unit or 350 mL) within 3 months prior to receiving the first dose of study medication.
  • Receipt of any prescription drug therapy within four weeks or over-the counter (OTC) drugs within two weeks prior to receiving the first dose of study medication or repeated use of drugs within the last four weeks.
  • An unusual diet, for whatever reason e.g. low sodium diet, for two weeks prior to receiving any medication and through out subject's participation in the study. Consumption of grapefruit-containing food or beverages within 7 days prior to receiving the first dose of study medication in both the periods Recent history of dehydration from diarrhoea, vomiting or any other reason within a period of 24 hours prior to the study. Female volunteers demonstrating a positive pregnancy screen or currently breast-feeding.
Both
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
India
 
NCT01052129
BE-137-NAPR-2005
No
Vice President - Research & Development, Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited
Not Provided
Principal Investigator: Dr. Umesh Dhakate, MBBS Wellquest Clinical Research
Dr. Reddy's Laboratories Limited
May 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP